- Previous Close
1.5780 - Open
1.5460 - Bid --
- Ask --
- Day's Range
1.4720 - 1.5780 - 52 Week Range
1.3640 - 2.7650 - Volume
8,465 - Avg. Volume
0 - Market Cap (intraday)
19.775M - Beta (5Y Monthly) 1.22
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7500 - Earnings Date Mar 27, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
www.advicenne.comRecent News: 3MM.F
View MorePerformance Overview: 3MM.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3MM.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3MM.F
View MoreValuation Measures
Market Cap
19.04M
Enterprise Value
34.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.10
Price/Book (mrq)
--
Enterprise Value/Revenue
10.35
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-264.93%
Return on Assets (ttm)
-57.00%
Return on Equity (ttm)
--
Revenue (ttm)
3.33M
Net Income Avi to Common (ttm)
-8.83M
Diluted EPS (ttm)
-0.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.97M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.61M